Scientific Industries Inc

Good day and welcome to the Scientific Industries Second Quarter Fiscal Year 2025 Financial Results Conference Call. All participants will be in listen only mode. Should you need assistance, please signal a conference specialist by pressing the star key followed by zero. After today's presentation, there will be an opportunity to ask questions. To ask a question, you may press star then one on your telephone keypad. To withdraw your question, please press star then two. Please note this event is being recorded. I would now like to turn the conference over to Joe Doremi, Managing Partner. Please go ahead.

Thanks, Michael. Good morning, and thank you all for joining us today to review Scientific Industries' financial results for the second quarter of 2025, ended June 30, 2025. With us today on the call are Helena Santos, Chief Executive Officer, Daniel Donadie, CEO of SBI, and John Moore, Chairman. After the conclusion of today's prepared remarks, we'll open the call for questions. Before we begin with prepared remarks, I would like to remind everyone, certain statements made by the management team of scientific industries during this conference call constitute forward-looking statements within the meaning of a private securities litigation reform act of 1995. Except for the statements of historical fact, this conference call may contain forward-looking statements that involve risks and uncertainty, some of which are detailed under risk factors in documents filed by the company with the Securities and Exchange Commission, including the annual report on Form 10-K for the year ended December 31, 2024. Forward-looking statements speak only as of the date the statements were made. The company can give no assurance that such forward-looking statements will prove to be correct. Scientific Industries does not undertake and specifically disclaims any obligation to update any forward-looking statements except as required by law. Now I'd like to turn the call over to Helena Santos, CEO of Scientific Industries. Helena?

Thank you, Joe, and thank you, everyone, for joining us today. This really is a historic time for our company where a 70-year-old chapter closes and a new one begins. Two weeks ago tomorrow, we sold our legacy Genie products division to a respected player in our industry, the O-House division of Mettler Toledo. Scientific Industries was founded on the promise that it had invented a unique product, and by the standards at that time, innovative and market worthy. And to its testament, the Vortex Genie is still today one of the most widely recognized and respected brands in the lab equipment industry. I want to take this opportunity to thank just some of our dedicated team that helped create and nurture a product line that is known for excellence in quality and service. Mr. Robert Nichols, our division president, Ms. Deborah Siegel, our VP of sales and marketing, and all the people behind the scenes who love the Genies and have gone above and beyond what's expected of them. These individuals will always be honored as part of the company's history. We've welcomed new friends from O-House into our lives, and jointly we've made a commitment to ensure that the Genie customers and suppliers will receive the same quality products that has made the Genie name a trusted brand. This was an important, targeted, strategic step to enabling the next chapter in our company's history, one that will define the future of scientific industries. So what is the future of scientific industries? How do we define the future for ourselves? Just like we were pioneers in vortexing technologies, we see ourselves as pioneers of AI-powered life science platforms. starting with our vivid computer vision-based automated pill counters, where we will focus on machine learning capabilities, features innovation, and subscription monetization. This roadmap will place us in the forefront of pill counting technology and ultimately providing shareholder value. Our tour bell division, which will continue to operate out of here in Bohemia, provides solid and predictable cash flows with realistic opportunity for growth. Next, and perhaps the more important platform for many of our shareholders, is our bioprocessing division, which is getting close to realizing its potential with the expectation of some very important product development milestones coming up, as Mr. Daniel Donadilla will discuss right after me. And finally, I would like to thank our shareholders for their unwavering support throughout our journey and evolution. None of this would be possible without you. I thank you, and now I turn it over to Daniel. Daniel?